Literature DB >> 22612656

A capillary electrophoresis sequencing method for the identification of mutations in the inverted terminal repeats of adeno-associated virus.

Cameron Mroske1, Hector Rivera, Taihra Ul-Hasan, Saswati Chatterjee, K K Wong.   

Abstract

Inverted terminal repeat (ITR) integrity is critical for the replication, packaging, and transduction of recombinant adeno-associated virus (rAAV), a promising gene therapy vector. Because AAV ITRs possess 70% GC content and are palindromic, they are notoriously difficult to sequence. The purpose of this work was to develop a reliable ITR sequencing method. The ITRs of two molecular clones of AAV2, pTZAAV and pAV2, were (1) sequenced directly from plasmid DNA in the presence of denaturant (direct sequencing method, DSM) or (2) first amplified in a reaction in which 7-deaza-dGTP was substituted for dGTP and the resultant amplification product sequenced (amplification sequencing method, ASM). The DSM and ASM techniques yielded clear chromatograms, read through the ITR hairpin, and revealed hitherto unreported mutations in each ITR. pTZAAV and pAV2 possess identical mutations at the upstream MscI site of the 5' ITR (T>G, nt 2) and the downstream MscI site of the 3' ITR (del. nt 4672-4679). The chromatograms for pAV2 also revealed that the ITRs of this construct were arranged in a FLOP/FLOP orientation. In addition, the DSM was successfully employed to recover ITR-chromosomal junction sequences from a variety of rAAV-transduced tissue types. Both the DSM and ASM can be employed to sequence through the AAV ITR hairpin, and both techniques reliably detect mutations in the ITR. Because the DSM and ASM offer a way to verify ITR integrity, they constitute powerful tools for the process development of rAAV gene therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22612656      PMCID: PMC4015221          DOI: 10.1089/hgtb.2011.231

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  22 in total

1.  Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.

Authors:  Artur V Cideciyan; Tomas S Aleman; Sanford L Boye; Sharon B Schwartz; Shalesh Kaushal; Alejandro J Roman; Ji-Jing Pang; Alexander Sumaroka; Elizabeth A M Windsor; James M Wilson; Terence R Flotte; Gerald A Fishman; Elise Heon; Edwin M Stone; Barry J Byrne; Samuel G Jacobson; William W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-22       Impact factor: 11.205

2.  Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA.

Authors:  E Lusby; K H Fife; K I Berns
Journal:  J Virol       Date:  1980-05       Impact factor: 5.103

3.  AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

Authors:  Peter A LeWitt; Ali R Rezai; Maureen A Leehey; Steven G Ojemann; Alice W Flaherty; Emad N Eskandar; Sandra K Kostyk; Karen Thomas; Atom Sarkar; Mustafa S Siddiqui; Stephen B Tatter; Jason M Schwalb; Kathleen L Poston; Jaimie M Henderson; Roger M Kurlan; Irene H Richard; Lori Van Meter; Christine V Sapan; Matthew J During; Michael G Kaplitt; Andrew Feigin
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182

Review 4.  Gene therapy using adeno-associated virus vectors.

Authors:  Shyam Daya; Kenneth I Berns
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

5.  Effect of gene therapy on visual function in Leber's congenital amaurosis.

Authors:  James W B Bainbridge; Alexander J Smith; Susie S Barker; Scott Robbie; Robert Henderson; Kamaljit Balaggan; Ananth Viswanathan; Graham E Holder; Andrew Stockman; Nick Tyler; Simon Petersen-Jones; Shomi S Bhattacharya; Adrian J Thrasher; Fred W Fitzke; Barrie J Carter; Gary S Rubin; Anthony T Moore; Robin R Ali
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

6.  Safety and efficacy of gene transfer for Leber's congenital amaurosis.

Authors:  Albert M Maguire; Francesca Simonelli; Eric A Pierce; Edward N Pugh; Federico Mingozzi; Jeannette Bennicelli; Sandro Banfi; Kathleen A Marshall; Francesco Testa; Enrico M Surace; Settimio Rossi; Arkady Lyubarsky; Valder R Arruda; Barbara Konkle; Edwin Stone; Junwei Sun; Jonathan Jacobs; Lou Dell'Osso; Richard Hertle; Jian-xing Ma; T Michael Redmond; Xiaosong Zhu; Bernd Hauck; Olga Zelenaia; Kenneth S Shindler; Maureen G Maguire; J Fraser Wright; Nicholas J Volpe; Jennifer Wellman McDonnell; Alberto Auricchio; Katherine A High; Jean Bennett
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

7.  Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.

Authors:  William W Hauswirth; Tomas S Aleman; Shalesh Kaushal; Artur V Cideciyan; Sharon B Schwartz; Lili Wang; Thomas J Conlon; Sanford L Boye; Terence R Flotte; Barry J Byrne; Samuel G Jacobson
Journal:  Hum Gene Ther       Date:  2008-10       Impact factor: 5.695

Review 8.  Adeno-associated viral vectors and their redirection to cell-type specific receptors.

Authors:  Stefan Michelfelder; Martin Trepel
Journal:  Adv Genet       Date:  2009       Impact factor: 1.944

9.  Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.

Authors:  Andrew Feigin; Michael G Kaplitt; Chengke Tang; Tanya Lin; Paul Mattis; Vijay Dhawan; Matthew J During; David Eidelberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

10.  Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.

Authors:  Francesca Simonelli; Albert M Maguire; Francesco Testa; Eric A Pierce; Federico Mingozzi; Jeannette L Bennicelli; Settimio Rossi; Kathleen Marshall; Sandro Banfi; Enrico M Surace; Junwei Sun; T Michael Redmond; Xiaosong Zhu; Kenneth S Shindler; Gui-Shuang Ying; Carmela Ziviello; Carmela Acerra; J Fraser Wright; Jennifer Wellman McDonnell; Katherine A High; Jean Bennett; Alberto Auricchio
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

View more
  3 in total

1.  Efficient Nuclease-free HR by Clade F AAV Requires High MOIs with High Quality Vectors.

Authors:  Saswati Chatterjee
Journal:  Mol Ther       Date:  2019-11-11       Impact factor: 11.454

2.  Stem cell-derived clade F AAVs mediate high-efficiency homologous recombination-based genome editing.

Authors:  Laura J Smith; Jason Wright; Gabriella Clark; Taihra Ul-Hasan; Xiangyang Jin; Abigail Fong; Manasa Chandra; Thia St Martin; Hillard Rubin; David Knowlton; Jeff L Ellsworth; Yuman Fong; Kamehameha K Wong; Saswati Chatterjee
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-17       Impact factor: 11.205

3.  Intra-embryo Gene Cassette Knockin by CRISPR/Cas9-Mediated Genome Editing with Adeno-Associated Viral Vector.

Authors:  Naoaki Mizuno; Eiji Mizutani; Hideyuki Sato; Mariko Kasai; Aki Ogawa; Fabian Suchy; Tomoyuki Yamaguchi; Hiromitsu Nakauchi
Journal:  iScience       Date:  2018-11-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.